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Abstract
Question
What evidence is available regarding the emerging and
investigational therapies for the treatment of metastatic
brain tumors?
Target population
These recommendations apply to adults with brain
metastases.
Recommendations
New radiation sensitizers
Level 2 A subgroup analysis of a large prospective ran-
domized controlled trial (RCT) suggested a prolongation of
time to neurological progression with the early use of
motexaﬁn-gadolinium (MGd). Nonetheless this was not
borne out in the overall study population and therefore an
unequivocal recommendation to use the currently available
radiation sensitizers, motexaﬁn-gadolinium and efaproxiral
(RSR 13) cannot be provided.
Interstitial modalities
There is no evidence to support the routine use of new or
existing interstitial radiation, interstitial chemotherapy and
or other interstitial modalities outside of approved clinical
trials.
New chemotherapeutic agents
Level 2 Treatment of melanoma brain metastases with
whole brain radiation therapy and temozolomide is rea-
sonable based on one class II study.
Level 3 Depending on individual circumstances there may
be patients who beneﬁt from the use of temozolomide or
fotemustine in the therapy of their brain metastases.
Molecular targeted agents
Level 3 The use of epidermal growth factor receptor
inhibitors may be of use in the management of brain
metastases from non-small cell lung carcinoma.
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Rationale
As can be gleaned by the data collected and the questions
assessed in the other papers in this guideline series, uni-
formly successful control of brain metastases has not been
achieved. Even in those selected cases of outstanding con-
trol, toxicity from the treatment itself can result inan overall
decrement in the person’s level of function. Fortunately
there is research proceeding on a number of fronts to
improve this situation. To provide some insight into these
investigative areas, modalities that have reached the point
of assessment by clinical trials warrant critical review.
The objectives of this paper are to assess both compar-
ative and non-comparative studies of the following thera-
pies that are still in the investigational stage (i.e., not
currently available outside of clinical trials). This will
include (1) the radiation sensitizers motexaﬁn-gadolinium
and RSR 13, (2) local modalities placed at the time of
surgical excision including local irradiation with the bal-
loon-based brachytherapy, stereotactically placed radiation
sources, and local chemotherapy with BCNU-impregnated
polymers, (3) the role of the chemotherapeutic agents
temozolomide and fotemustine, and (4) the molecular tar-
geted agents against epidermal growth factor or angiogenic
receptors.
Methods
Search strategy
The following electronic databases were searched from
1990 to September 2008 MEDLINE
 , Embase
 , Cochrane
Database of Systematic Reviews, Cochrane Controlled
Trials Registry, Cochrane Database of Abstracts of
Reviews of Effects. A broad search strategy using a com-
bination of subheadings and text words was employed. The
search strategy is documented in the methodology paper
for this guideline series by Robinson et al. [1]. Reference
lists of included studies were also reviewed.
Eligibility criteria
For literature to be included for consideration in creation of
the guidelines related to this question, it needed to meet the
following criteria:
• Published in English.
• Include patients with brain metastases.
• Arise from fully-published primary studies with a
publication date of 1990 forward or abstracts from the
2006–2008 meetings of AANS, CNS, SNO, ASTRO,
ASCO and the AANS/CNS joint section on tumors
satellite symposiums (all study designs for primary data
collection were included; e.g., randomized controlled
trials, non-randomized trials, cohort studies, case–
control studies, or case series).
• Evaluation of one or more or the following modalities
was necessary:
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123• Radiation sensitizers:
• Motexaﬁn-gadolinium
• Efaproxiral (RSR 13)
• Local modalities placed at the time of surgical excision
or biopsy:
• Local irradiation
• Balloon tipped catheter placement
• Interstitial radiosurgery or brachytherapy (with-
out hyperthermia)
• Local chemotherapy to the resection cavity
• New chemotherapeutic agents: temozolomide or
fotemustine
• Molecular targeted agents: Geﬁtinib (ZD1839)
• Anti-angiogenesis agents: Bevacizumab (Avastin)
• The number of study participants with brain metastases
needed to be[5 per study arm for at least two of the
study arms for comparative studies and[5 overall for
non-comparative studies.
• The following criteria was applied to full-length papers,
but not meeting abstracts: For studies evaluating
interventions exclusively in patients with brain metas-
tases, the baseline characteristics of study participants
needed to be provided by treatment group for compar-
ative designs and overall for non-comparative studies.
For studies with mixed populations (i.e., includes
participants with conditions other than brain metasta-
ses), baseline characteristics needed to be provided for
the sub-group of participants with brain metastases, and
stratiﬁed by treatment group for comparative studies.
Study selection and quality assessment
Two independent reviewers evaluated citations using a pri-
ori criteria for relevance and documented decisions in
standardized forms. Cases of disagreement were resolved
by a third reviewer. The same methodology was used for
full text screening of potentially relevant papers. Studies
which met the eligibility criteria were data extracted by one
reviewer and the extracted information was checked by a
secondreviewer.The PEDroscale [2,3] was used torate the
quality of randomized trials. The quality of comparative
studies using non-randomized designs was evaluated using
eight items selected and modiﬁed from existing scales.
Evidence classiﬁcation and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the American
Association of Neurological Surgeons (AANS)/Congress
of Neurological Surgeons (CNS) criteria. These criteria are
provided in the methodology paper accompanying this
guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of questions to be
answered regarding the practice guidelines on the manage-
mentofbrainmetastasesbasedonasystematicreviewofthe
literature conducted in collaboration with methodologists at
the McMaster University Evidence-based Practice Center.
Scientiﬁc foundation
Overall, 59 publications (53 primary studies and 6 com-
panion papers) met the eligibility criteria for use in the
discussion of the scientiﬁc foundation of this guideline
(Fig. 1). A summary of the class of evidence of all the
primary studies discussed in this scientiﬁc foundation are
presented in Table 1.
New radiation sensitizers
Review of the literature provided ﬁve unique studies [4–8]
and ﬁve companion papers [9–13] that met the criteria for
support of guidelines recommendations regarding the use
of new radiation sensitizers in the management of brain
metastases (Table 2).
Many radiation sensitizers have been investigated to try
to increase the effectiveness of whole-brain radiation
therapy (WBRT). Two recent radiation sensitizers that
have been extensively evaluated are motexaﬁn gadolinium
and efaproxiral.
Motexaﬁn gadolinium
Motexaﬁn gadolinium (MGd) is a metallotexaphrin that
localizes within tumors in greater concentration than in nor-
mal tissues. This agent is detectable by magnetic resonance
imaging (MRI) because it contains the paramagnetic metal
ion, gadolinium. Its exact mechanism of action is not known
althoughitisknowntobeinvolvedwithelectronscavenging.
It may act as both a radiation sensitizer and modiﬁer.
There is one prospective single arm study [7] (class III
evidence) and two randomized controlled studies [4, 6]
(class I evidence) evaluating MGd as a radiation sensitizer.
Carde et al. published a prospective single arm phase Ib/II
study which established MGd 5 mg/kg given intravenously
daily as the recommended best tolerated dose when
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3 Gy. This yielded class III evidence regarding the feasi-
bility and potential efﬁcacy of MGd [7].
Asubsequentrandomizedcontrolledstudyin401patients
with brain metastases of various histologies, comparing
WBRT alone versus WBRT with motexaﬁn gadolinium
failedtoshowanysigniﬁcantdifferenceinmediansurvivalor
tumor response [4]. However, the median time to neurologic
progressionasdeterminedbytheinvestigatorswasincreased
by 0.5 months (p = 0.018) for the group that received mo-
texaﬁngadolinium.This effectwasattributedpredominantly
to the lung cancer stratum. Patients were stratiﬁed by his-
tology (lung, breast or other) and a subset analysis revealed
that the time to neurological progression favored the MGd
and WBRT arm for patients with lung cancer (median
5.5 months for MGd v 3.7 months for WBRT alone,
p = 0.025), but no difference was seen in the other strata. A
companionstudyofneurocognitivefunctionbyMeyersetal.
further suggested that MGd may preserve memory and
executive function and prolong time to neurocognitive and
neurologicprogressioninpatientswithbrainmetastasesfrom
lung cancer [9].
An international phase III study was therefore conducted,
randomizing 554 patients with non-small cell lung
carcinoma(NSCLC)toWBRTalone(30 Gyin10fractions)
or to WBRT with MGd [6]. The primary endpoint of the
study was time to neurologic progression. Although time to
neurological progression was improved in the MGd arm, it
was not a statistically signiﬁcant difference unless the
patientsenrolledoutsideofNorthAmericawereexcluded.In
a subgroup analysis of the 348 North American patients,
there was a statistically signiﬁcant prolongation of time
to neurological progression from 8.8 to 24.2 months,
p = 0.04. This difference in outcome between the North
American patients and patients treated elsewhere was
attributed to the fact that patients in North America received
the study treatment sooner after the diagnosis of the brain
metastases.WhenWBRTwasinitiatedwithinthreeweeksof
diagnosis of the brain metastases, regardless of whether the
patient was treated in North America or not, time to neuro-
logical progression was signiﬁcantly prolonged by the addi-
tionofMGd(p = 0.006,HR = 0.59).Amajorreasonforthe
delay to WBRT outside of North America was the use of
chemotherapy. This study failed to meet its primary objec-
tive of increasing time to neurologic progression and is
considered a negative study. However the subgroup analysis
mentioned, though post hoc and selective in nature, can be
interpreted as providing class 2 evidence.
Title and Abstract 
Screening
n=16,966 
Full Text 
Screening
Excluded at Title 
and Abstract
n=16,841
Eligible Studies
n=59 
66 Excluded 
No extractable data…………………………………………...2 
No baseline patient data by treatment/ BM sub-group……….32 
No treatment comparison of interest…………………………14 
≤ 5 patients with brain metastases /group................................16 
Commentary / Practice point…………………………………2 
59 Included
Chemotherapy…………………………………….31 
Interstitial Modalities……………………………..12 
[11 unique studies, 1 companion study] 
Radiation Sensitizers……………………………...10 
[5 unique studies, 5 companion studies] 
Molecularly Targeted Agent……………………....6 
Anti-angiogenesis Agent ………………………….0 
Fig. 1 Flow of studies to ﬁnal
number of eligible studies
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123Efaproxiral
Efaproxiral, (also known as RSR13; Allos Therapeutics,
Westminster, CO) is an allosteric modiﬁer of hemoglobin.
Efaproxiral binds to hemoglobin, causing a change in its
conformational structure, leading to a reduction in
hemoglobin oxygen binding afﬁnity. This leads to an
increased release of oxygen into tissue, enhancing tumor
Table 1 The evidence class provided by the included primary studies
Evidence class Description of evidence class Class of evidence provided by included primary studies
New radiation sensitizers: motexaﬁn-gadolinium and efaproxiral
Class I Evidence provided by one or more well-designed
randomized controlled clinical trials, including overview
(meta-analyses) of such trials
3 RCTs: Mehta [4], Suh [5], Mehta [6]
Class II Evidence provided by well-designed observational studies
with concurrent controls (e.g. case control and cohort
studies)
None
Class III Evidence provided by expert opinion, case series, case
reports and studies with historical controls
1 Prospective cohort study with historical controls: Shaw [8]
1 Prospective single arm study: Carde [7]
Interstitial modalities
Class I Evidence provided by one or more well-designed
randomized controlled clinical trials, including overview
(meta-analyses) of such trials
None
Class II Evidence provided by well-designed observational studies
with concurrent controls (e.g. case control and cohort
studies)
1 Retrospective cohort study: Ostertag [25]
Class III Evidence provided by expert opinion, case series, case
reports and studies with historical controls
3 Prospective single arm studies:
Ewend [15], Rogers [16], Nakagawa [17]
7 Case series: Alesch [18], Bernstein [19], Bogart [20],
Dagnew [21], Schulder [22], Curry [23], Nakamura [24]
New chemotherapeutic agents: Temozolomide or fotemustine
Class I Evidence provided by one or more well-designed
randomized controlled clinical trials, including overview
(meta-analyses) of such trials
1 RCT: Mornex [59]
2 Randomized phase II trials: Antonadou [32], Verger [33]
Class II Evidence provided by well-designed observational studies
with concurrent controls (e.g. case control and cohort
studies)
2 Retrospective cohort studies: Conill [34], Panagiotou [35]
Class III Evidence provided by expert opinion, case series, case
reports and studies with historical controls
22 Prospective single arm studies: Abrey [36], Addeo [37],
Agarwala [38], Caraglia [41], Christodoulou [42],
Christodoulou [43], Cortot [56], Giorgio [44], Hwu [46],
Iwamoto [47], Janinis [48], Kouvaris [49], Krown [50],
Larkin [51], Margolin [52], Omuro [53], Rivera [54],
Schadendorf [55], Brocker [60], Chang [61], Cotto [62],
Jacquilat [63]
2 Case series: Hofmann [45], Ulrich [64]
2 Sub-group analyses of prospective studies: Bafaloukos
(2006),
Boogerd [40]
Molecular targeted agent: Geﬁtinib (ZD 1839)
Class I Evidence provided by one or more well-designed
randomized controlled clinical trials, including overview
(meta-analyses) of such trials
None
Class II Evidence provided by well-designed observational studies
with concurrent controls (e.g. case control and cohort
studies)
None
Class III Evidence provided by expert opinion, case series, case
reports and studies with historical controls
3 Prospective single arm studies: Ceresoli [71],
Chiu [72], Wu [73]
3 Case series: Hotta [68], Namba [69], Shimato [70]
Fully published papers. Conference proceeding abstracts not included
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123oxygenation leading to radiation sensitization. Shaw et al.
completed a phase II study in which 57 patients with
brain metastases received WBRT (30 Gy in 10 fractions
of 3 Gy) with daily efaproxiral 50–100 mg/kg. This
yielded class III data showing median survival was
6.4 months which compared favorably to the Radiation
Therapy Oncology Group’s (RTOG) historical control
patients (4.1 months) [8].
This prompted a large phase III study of WBRT alone
versusWBRTwithefaproxiralin515patients[5].Thisstudy
failed to reveal a signiﬁcant difference in median survival,
tumor response or median time to recurrence/progression
with the addition of efaproxiral although it prompted a
conﬁrmatorytrialinpatientswithbrainmetastasesrelatedto
breast cancer. The investigators found that patients with
brain metastases related to breast cancer were more likely to
receive at least 7 of the planned 10 fractions of efaproxiral
and were more likely to have an increased concentration of
efaproxiral in red blood cells as compared to patients with
brain metastases due to other primary cancers such as lung
cancer[11,12].However,theconﬁrmatoryphaseIIIstudyin
breast cancer patients of WBRT with efaproxiral versus
WBRT alone failed to demonstrate an improvement in
overall survival or any other prespeciﬁed endpoint [13, 14].
In summary, there is class I evidence that motexaﬁn
gadolinium (MGd) given daily during WBRT does not
increase survival over survival following WBRT alone.
Additionally, there is also class I evidence that efaproxiral
given daily during WBRT does not increase survival over
survival following WBRT alone.
Radiation sensitizers summary
Considerable effort has been put into the development of
motexaﬁn gadolinium and efaproxiral yielding class I data
supporting the conclusion that these agents do not improve
the therapy of brain metastases. This is not to say that
radiation sensitizers are without merit. The lessons learned
in the studies reviewed here provide direction for further
investigation and encouraging patient participation in such
studies is warranted.
Interstitial modalities
Review of the literature provided 11 unique studies [15–25]
and one companion study [26] that met the criteria for
support of guidelines recommendations regarding the use of
interstitial modalities in the management of brain metasta-
ses (Table 3). In this discussion brachytherapy is deﬁned as
therapy placed inside of or next to the area being treated.
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which the therapy speciﬁcally consists of radiation.
Brachytherapy with or without whole brain radiation
therapy
One retrospective series [25] looking at three cohorts and
two case series [18, 19] met criteria for inclusion of their
data in this portion of the guideline.
Retrospective multiple cohort series
In a retrospective cohort study [25] of the temporary
implantation of
125I seeds for spherical brain metastases
(from a variety of primary sites) 4 cm or smaller in diameter
Ostertag et al. looked at three groups of patients that the
authors refer to as A, B and C, respectively, with A being
temporary
125I seeds and WBRT for patients with newly
diagnosed brain metastases, B being temporary
125I seeds
alone in patients newly diagnosed with brain metastases,
and C being temporary
125I seeds for patients with recurrent
brain metastases treated with other modalities ﬁrst. The
chosen dose of interstitial radiation was 60 Gy prescribed to
the rim of the lesion(s). The dose of WBRT was chosen to
be 40 Gy in 2 Gy daily fractions. In terms of clinical
characteristics, three cases with two lesions were treated in
the ﬁrst group, four cases with two lesions were treated in
the second group and twelve cases with two lesions were
treated in the third group. The groups were balanced except
for age. The median age was 55 years, 58 years, and
47 years, by group, respectively, with a statistically sig-
niﬁcant younger age for the third group. Median survivals
for the three groups were 17, 15 and 6 months, respectively.
The shorter survivals in those with recurrent and longer
standing disease was not considered surprising. The dif-
ference between the ﬁrst two brachytherapy groups (with or
without WBRT, respectively) was not signiﬁcant using
Lee–Desu statistic to assess the Kaplan–Meier survival
curves. The authors state that the temporary
125I sources
utilized in the manner outlined were not associated with
radiation necrosis requiring surgery in any case. They go
onto advocate ‘‘interstitial radiosurgery’’ as a method of
avoiding or postponing WBRT. The properly executed
retrospective comparison of the cohorts treated here yielded
class II evidence. However, the numbers treated in each
group are moderate in nature and no comparison to meta-
static tumors treated in a more standard method is provided.
Thus, a level 2 recommendation cannot be provided [25].
Case series
In a case series of 19 patients, Alesch et al., describe their
use of temporary
125I seeds treating metastases from a
variety of primary lesions with a tumor margin dose of
60 Gy. All but one case had one lesion. A mean dose rate
of 11 cGy/hour (ranging from 5 to 22 cGy/hour) was used
and the mean irradiation time before explantation was
28 days (ranging from 11 to 52 days). They utilized a
simplistic plan with only one catheter per lesion. The
authors point out the value of biopsy at the time of implant
to rule out other processes, which excluded three cases
from their series. CT was the predominant modality used
for imaging and response assessment, leaving the possi-
bility of other untreated small lesions open to question. The
responses were classiﬁed as marked reduction (5 cases),
slight reduction (11 cases), unchanged (2 cases) and not
evaluable (1 case). Marked reduction versus slight reduc-
tion was not deﬁned further. One patient had a temporary
worsening of an existing hemiparesis. No patient died from
neurologic causes. No mention of symptomatic radiation
necrosis is provided. As this report is a case series it meets
the criteria for class III evidence [18].
In a small series of ten cases of single brain metastases
that had recurred at the same site after surgical resection
and WBRT Bernstein et al. describe the use of high activity
125I seeds used to administer 70 Gy or more at periphery of
the lesion at a median dose rate of 67 cGy/h. Nine of the
cases had lung primaries. The median time to tumor
recurrence was 35 weeks. Median survival was 46 weeks.
Reoperation at the implant site was necessary in three cases
because of symptomatic mass effect, two for radiation
necrosis and one for mixed tumor and radiation necrosis.
Two early deaths occurred from pulmonary emboli. The
authors point out that the cases were highly selected and
conclude that a more detailed controlled and randomized
study compared to other therapies is necessary to assess the
real value of this mode of therapy in brain metastases. This
case series with no comparative component meets the cri-
teria to provide class III evidence [19]. This and the cases
series by Alesch et al. support the feasibility of this
modality but do not provide evidence of comparative
efﬁcacy necessary to more strongly support its recom-
mendation [18].
Surgery and brachytherapy
One fully published single arm phase II study [16] and
three case series [20–22] met criteria for inclusion of their
data in this portion of the guideline.
Phase II single arm studies
To look at the efﬁcacy of the Gliasite Radiation Therapy
System after surgical resection of single brain metastases
Rogers et al. designed a phase II study. This system entails
surgical placement of a balloon that is connected to a
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123reservoir that is implanted subcutaneously. Liquid con-
taining
125I is then inserted postoperatively into the balloon
by injection into the reservoir. Patients were required to
have a single resected lesion and to have a Karnofsky per-
formance score (KPS) of 70 or above. Fifty-four cases with
tumors from a variety of primary sites were enrolled with a
median age of 60 and a median KPS of 90. The planned
dose of radiation was 60 Gy to a one cm depth from the
balloon surface. One year local control rate was the primary
outcome assessed and was 79%. Distant brain control at the
same interval was 50% with median time to development of
those distant lesions being 54 weeks. Histologically con-
ﬁrmed radiation necrosis alone was observed in nine cases
and in two others in combination with tumor recurrence.
They estimated the actuarial 1 year incidence of radiation
necrosis without tumor at 23%. The authors made an
attempt to assess functional status noting baseline median
Mini-Mental Status Exam scores were 28.5. This remained
stable at29at6 months and 12 months amongst the patients
still surviving at those intervals. Additionally the median
FACT-BR score at baseline was 130 and at 12 months it
was 112. Median survival was 40 weeks at the 1 year fol-
low-up point of the report and only four of the 35 deaths that
had occurred were due to tumor progression within the
central nervous system and all were at sites not treated with
the Gliasite. This data was obtained prospectively, but
without meaningful concurrent comparative data rendering
it class III evidence [16].
Sills et al. provided a preliminary report captured in a
conference proceeding search of a series of patients with
one to three brain metastases. One lesion was treated with
‘‘balloon brachytherapy’’ (presumably the Gliasite Radia-
tion Therapy System) to a dose of 60 Gy at 5 mm and the
other lesions treated with stereotactic radiosurgery. Of the
48 cases reported (of a planned enrollment of 50) one case
had local recurrence at 3 months and another at 9 months.
Radiation necrosis was conﬁrmed surgically in one case
12 months after treatment and suspected by positron
emission tomography in another after 15 months. The
primary outcome measures planned were 6 month and
1 year local control and this was not reported. This data
was obtained prospectively, but is clearly incomplete and
without meaningful concurrent comparative data rendering
it as class III evidence [27].
In another preliminary report captured in a conference
proceeding search, a study assessing radiation necrosis in
brain metastases patients by Burri et al. provided a retro-
spective look in their practice database of 20 cases that
underwent resection followed by Gliasite implantation as
initial primary therapy without WBRT. The chosen dose
was 60 Gy though the depth of the dose is speciﬁed in only
seven of the cases. Seven cases required surgical debride-
ment of symptomatic progressive imaging changes that
proved to be radiation necrosis for a crude reoperation rate
of 35%. They attempted to estimate an actuarial risk of
reoperation in those with radiation necrosis noting it as 7%
at 6 months reaching 84% at 24 months with a median
time to that operation of 17 months. The authors conclude
that radiation necrosis is a substantial risk with the use of
the Gliasite device for the dose regimens they used for
metastatic disease. The retrospective nature of this series is
unable to ﬁlter for bias in case selection or nonsurgical
management and provides no comparison to other modal-
ities of radiation to determine if their ﬁndings are truly out
of the ordinary for their practice. Thus this case series with
limited clinical background and no comparative component
meets the criteria to provide class III evidence [28]. The
frequency of radiation necrosis with the use of Gliasite was
substantial in the Rogers et al. [16] and the Burri et al. [28]
studies. Additionally, the minimally described assessments
for radiation necrosis in the Sills et al. [27] study results in
the level 3 recommendation that this technique is best
utilized in the clinical trial setting for metastatic brain
tumors.
Case series
Bogart et al., report a series of 15 cases of solitary
metastases from NSCLC treated with surgical resection
and permanent
125I seeds implanted on the surface of the
tumor bed. Median KPS was 70 and ten of the 15 indi-
viduals had the intracranial disease as the only active site.
The planned dose was 5 cGy/h with estimated cumulative
doses of 80–160 cGy to the tumor bed [29]. Median fol-
low-up and survival was 14 months. The median time to
recurrence was 9 months. Recurrences within the brain
were local in 2 l, distant in two and both in one. One
individual succumbed to an overwhelming fungal infec-
tion. None developed symptomatic radionecrosis. The
authors conclude that this modality may be useful for
selected patients but that further studies in a larger number
of patients were warranted [20].
When looking at a series of 26 patients with single brain
metastasis with very high performance status (median KPS
90) Dagnew et al. [21], found a median actuarial survival of
17.8 months after surgical resection and placement of per-
manent low activity
125I seeds with an estimated dose of
150 Gy to the tumor bed resection perimeter taking into
account tumor cavity collapse. All cases reportedly had
controlled systemic disease from a variety of primary sites.
Only one patient had local recurrence and only two died of
neurologic disease. Thirty-eight percent developed tumors
elsewhereinthebrainthatontheirreviewwashigherthanin
patients who received WBRT as an initial part of their
treatment (as previously seen in studies by Noordijk et al.
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thrombosis and pulmonary embolus perioperatively.
Symptomatic radiation necrosis occurred in two individuals
requiring surgical debridement. Both of those patients had
tumors that had exceeded 3 cm in greatest diameter (3.1 and
5 cm). This case series with no comparative component
meets the criteria to provide class III evidence [21].
In 1997 Schulder et al., reported their experience with 13
cases of brain metastases treated with surgical resection and
implantation of permanent low activity
125I seeds. Included
wereindividualswithrecurrenttumorshavingalreadyfailed
WBRT(8patients),orwhohadinitiallyrefusedWBRTwith
metastases too large for stereotactic radiosurgery (5
patients). The median calculated dose of
125I was 82 Gy.
This was a good performance status group of patients with a
mean KPS of 84 and absent or stable systemic disease. Two
patients died early; one who required evacuation of a
hematoma in the resection cavity on the day after implan-
tationthendiedofpulmonaryembolus2 weekslaterandone
with postoperative adult respiratory distress syndrome. The
mean survival of the remaining 11 was 9 months and all had
local control. One individual required surgery for symp-
tomatic radiation necrosis and another for a combination of
tumor and radiation necrosis. One patient developed a
symptomatic cerebrospinal ﬂuid leak requiring repair. This
case series with no relative comparison to another therapy
meetsthecriteriatoprovideclassIIIevidence[22].Thehigh
earlymortalityrateinthissmallstudysuggeststhattheuseof
low activity
125I seeds in brain metastases should be rele-
gated to properly conducted clinical trials.
Surgery and local chemotherapy with or without whole
brain radiation therapy
Two single arm studies [15, 17] met the criteria for
inclusion of their data in this portion of the guideline.
In an assessment of an alternative modality to local
radiation therapy, Ewend et al., described their experience
with a prospectively evaluated group of 25 cases of newly
diagnosed solitary metastatic tumors in good performance
status patients treated with surgical resection and Gliadel
wafer implantation followed by WBRT (44 Gy in 22
fractions). The primary goal was to assess toxicity of this
combination therapy, and the serious toxicities reported
included seizures (n = 1), seizures and respiratory failure
(n = 1), and the moderate toxicities included nausea
(n = 2), constipation (n = 3), right eye pain (n = 1) and
fever (n = 1). Median follow-up was 36.1 weeks and at
that point median survival was 33 weeks. No local recur-
rences were reported but four patients developed distant
intracranial recurrences and two patients had new metas-
tases in the spinal canal. Of the 16 deaths observed ﬁve
were neurologic in nature. This data was obtained
prospectively, but without meaningful concurrent com-
parative data rendering class III evidence [15].
In a study of the feasibility of intracavitary 5-ﬂuoro-20-
deoxyuridine (FdUrd) Nakagawa et al., report on six brain
metastases patients in a series of 13 cases with malignant
brain tumors. They point out that the goal of the use of this
agent is to inhibit tumor DNA synthesis by its metabolite
5-ﬂuoro-2’deoxy-5’-monophosphate. After claiming to
show intrathecal administration of FdUrd was safe, the
authors placed an Ommaya reservoir in ‘‘small’’ fresh
resection cavities and then administered 25–30 daily
injections of 1–5 micrograms. They report no adverse
events and three complete responses (of 3, 10 and
32 weeks, respectively), one with stable disease and two
with progressive disease. However, median follow-up time
is not reported. This data was obtained prospectively, but
with less than usual detail on pretreatment and post-treat-
ment data and is without meaningful concurrent compara-
tive data rendering it as class III evidence [17].
Interstitial radiosurgery
Twocaseseries[23,24]metthecriteriaforinclusionoftheir
data in this portion of the guideline. To assess a device
termed the Photon Radiosurgery System (PRS), Curry et al.,
describe its use in the treatment of 60 patients with meta-
static brain tumors; 37 with solitary lesions and 23 with
multiple lesions. They describe the device as a light weight
x-ray generator that produces a point source of low-energy
photons.Themedianageofthesubjectswas58 years(range
of 18–83 years) and median KPS was 90. Prior treatment
was variable. PRS was applied in cases not deemed suitable
for resection due to location or which were undergoing
diagnostic biopsy. Seven lesions were larger than 3 cm in
diameter and only one in the entire series was in the cere-
bellum. The device was introduced utilizing a stereotactic
frame. The median dose was 16 Gy to a point 2 mm beyond
the enhancing tumor margin. The authors chose to report
local control as their primary outcome and did so after a
median follow-up of 6 months (with a range of 5 days to
31 months).Seventy-twolesionsweretreated.Localcontrol
was present in 81%. Median survival was 8 months from
treatment. Of the 46 cases that went onto death, 30% were
neurologic in nature. Four patients experienced periopera-
tive seizures that were easily controlled with anticonvulsant
medications and were not recurrent, three experienced
transient neurological deﬁcits thought to be associated with
the biopsy or due to treatment induced cerebral edema, and
two experienced biopsyrelated hemorrhages.Three patients
experienced symptomatic radiation necrosis requiring sur-
gical debridement and corticosteroid therapy. This case
series with no concurrent comparison to another therapy
meets the criteria to provide class III evidence [23].
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123In an attempt to avoid WBRT as an initial treatment in
patients with metastatic brain tumors Nakamura et al.,
reported a case series of 43 patients whose solitary lesions
were treated with intraoperative radiosurgery with high-
energy electron beams generated by a 20 MeV betatron.
Therapy was delivered over 5–10 min to a dose of
18–25 Gy with 8–16 MeV to one cm beyond the margins of
a fresh resection bed. They also mention that progression
was treated with additional radiation but this was not stan-
dardized. One year survival was 53%. Median follow-up
was not reported, but seven patients developed local recur-
renceandseven patientsdevelopedbrainrecurrencesdistant
from the primary site. Two individuals developed radiation
necrosis at the treatment site but were managed without
surgery. The authors discuss other patients treated for brain
metastases at their institution utilizing various combinations
of therapy but fail to provide systematic pretreatment and
follow-updatasoastomakeameaningfulcomparison.Thus
the data from this paper qualiﬁes as class III evidence [24].
Interstitial therapy summary
Interstitial therapies are appealing as their intent is to
maximize treatment of the metastatic pathology and pre-
serve surrounding normal tissue. The data presented here
does not allow creation of level 1 or level 2 recommen-
dations. The interstitial use of radiation and cytotoxic
chemotherapy appears feasible but not without toxicity.
Furtherance of these modalities will be dependent on truly
prospective and comparative study designs in order to
obtain meaningful information.
New chemotherapeutic agents
Review of the literature provided 31 unique studies that
met the criteria for support of guidelines recommendations
regarding the use of chemotherapeutic agents in the man-
agement of brain metastases (Table 4). The use of tem-
ozolomide was reported in 25 studies of which two were
evidence class I studies [32, 33], two were evidence class II
studies [34, 35], and 21 were evidence class III studies
[36–56]. In most of the studies included in this discussion
the primary tumor treated was melanoma, though other
primary tumor sites were addressed.
Temozolomide
Prospective randomized phase II studies
In the ﬁrst of the class I studies Antonadou et al., carried out
a randomized phase II study of 48 individuals with lung
cancer, breast cancer or unknown primaries. Group 1
received WBRT to 40 Gy in 2 Gy fractions and group 2
receivedoral temozolomide(TMZ, 75 mg/m
2/d) concurrent
with WBRT 40 Gy in 2 Gy fractions and then continued
TMZtherapy(200 mg/m
2/d)for5 daysevery28 daysforan
additional maximum of 6 cycles after WBRT was com-
pleted. The clinical and pathologic characteristics of the
groupswerewellbalanced.Theresponserateingroup2was
96% as opposed to 67% in group 1, a signiﬁcant difference
(p = 0.017). This better response rate was at the cost of
signiﬁcantly more nausea and vomiting in group 2. There
was no grade 3 or grade 4 myelosuppression. However,
median survival was 7.0 months in group 1 and 8.6 months
in group 2, a difference that did not reach signiﬁcance [32].
The second class I study by Verger et al., was also a
randomized phase II study of patients with newly diag-
nosed brain metastases from any source. Group 1 received
30 Gy WBRT in 10 fractions and group 2 received 30 Gy
WBRT in 10 fractions with concurrent TMZ during radi-
ation (75 mg/m
2/day), followed by two cycles of TMZ
(200 mg/m
2/day) for 5 days of a 28 day cycle. The clinical
and pathology characteristics of each group were not sig-
niﬁcantly different. Progression free survival from brain
metastases 90 days after randomization was 72% in group
2 and 54% in group 1, a statistically signiﬁcant advantage
(p = 0.03). Also group 1 had a greater percentage dying a
neurologic death (69%) than in group 2 (41%), again a
signiﬁcant difference (p = 0.029). Despite these differ-
ences, there was no advantage in median survival of group
2 over group 1 (4.5 months and 3.1 months, respectively)
and no difference in response rates. Additionally, clinically
signiﬁcant toxicity was only observed in group 2 [33]. In
summary, neither of these well done randomized phase II
studies demonstrated a meaningful beneﬁt to survival by
adding TMZ.
Retrospective cohort analyses
Both of the class II studies regarding the use of TMZ were
retrospective cohort analyses [34, 35]. In the ﬁrst study
Panagioutou et al., described their experience with 64
patients with melanoma brain metastases. Four groups
were evaluated according to treatment. Group A was
treated with surgery followed by WBRT, Group B was
treated with TMZ at initial diagnosis and with WBRT at
progression, Group C was treated with WBRT alone, and
Group D received supportive care alone. The median sur-
vivals were 12, 5, 3, and 2 months, respectively. The sur-
vival in the TMZ at initial diagnosis and WBRT at
progression group was signiﬁcantly greater than the WBRT
alone group (p = 0.0267 by log rank). Patient character-
istics inﬂuenced treatment selection. Age and intracranial
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123extent of disease were not well balanced and performance
status was not assessed [35]. In a study that mainly looked
at differing radiation doses Conill et al., reviewed a group
of 21 individuals with melanoma brain metastases who
were treated with WBRT (20 Gy in 5 fractions) and TMZ-
based chemotherapy (n = 11), or WBRT (30 Gy in 10
fractions) and TMZ-based chemotherapy (n = 11). The
actual chemotherapy regimens varied substantially, with
some patients receiving other agents in addition. The extent
of disease and performance status was reasonably well
balanced between the two groups and the median survival
in both groups was 4 months [34]. Again, in these class II
studies, one cannot conclude TMZ imparts a survival
advantage.
Prospective phase II studies
Among the 21 remaining studies qualifying for inclusion in
this guideline all were class III data. Five were prospective
phase II studies in which TMZ was utilized alone [36, 38,
43, 44, 55]. Agarwala et al., reported their prospective
experience with 151 patients with newly diagnosed brain
melanoma metastases treated with TMZ (150 mg/m
2/day
for patients with prior chemotherapy, or 200 mg/m
2/day
for chemotherapy naı ¨ve patients, for 5 days, every 28 days
for 1 year or until disease progression or unacceptable
toxicity). Median survival was 3.2 months and objective
response (complete response or partial response) was noted
in 6% [38]. Schadendorf et al., treated 45 individuals with
known melanoma who had developed new brain metastases
with TMZ (125 mg/m
2/day in patients who had received
prior chemotherapy or 150 mg/m
2/day in previously
untreated patients, on days 1–7 and days 15–21 very
28 days). Median survival was 4.1 months with two partial
responses and ﬁve patients with stable disease [55]. In
another study of newly diagnosed brain metastases
Christadoulou et al. looked at individuals with a wide
variety of primaries that had already received substantial
systemic therapy for their cancer. All (n = 28) received
TMZ (150 mg/m
2/day for 5 days every 4 weeks until
progression or unacceptable toxicity). Median survival in
the entire group was 4.5 months with only one partial
response [43]. Abrey et al., looked at 41 individuals with
recurrent or progressive brain metastases from various
primaries (22 were NSCLC) treated with TMZ (patients
who had received chemotherapy before received TMZ
150 mg/m
2/day for 5 days, and chemotherapy naı ¨ve
patients received 200 mg/m
2/day for 5 days with treatment
cycles repeated every 28 days). Two partial responses were
observed. Overall median survival was 6.62 months in all
participants [36]. Giorgio et al., looked at a series of
patients with NSCLC whose brain metastases had pro-
gressed after WBRT and one regimen of chemotherapy
(n = 30). Two complete responses and one partial
response were reported. Median survival was six months
[44]. Though individuals with NSCLC seemed to survive
slightly longer than those with melanoma in these ﬁve
studies no meaningful comparison or statistical assessment
can support such a conclusion.
In a sixth prospective single armed study Janinis reported
on 11 patients with melanoma brain metastases who had not
received radiotherapy, who were treated with TMZ
(200 mg/m
2/day for 5 days every 28 days for chemother-
apy naı ¨ve patients and 150 mg/m
2/day for 5 days every
28 days for patients treated with prior chemotherapy).
Survivals ranged from 10 days to over 13 months but no
median was reported [48]. Though this publication met the
criteria for being included in this guideline, the small size
and lack of comparative data does not yield information that
provides direction for therapy in brain metastases.
In three of the prospective phase II studies yielding class
III data, TMZ was used with WBRT [37, 49, 52]. Margolin
et al., assessed 31 individuals with newly diagnosed mela-
noma brain metastases treated with TMZ at 75 mg/m
2/day
started on day 1 and continued daily for 6 weeks and then
repeated every 10 weeks along WBRT to a total dose of
30 Gy in 10 fractions on days 1–5 and 8–12. Though all
cases had a WHO performance status of 0 or 1 the median
survival was just 6 months and only one complete response
and two partial responses were observed [52]. In a more
recent study Addeo et al., describe the use of WBRT to a
dose of 30 Gy in 10 fractions with concomitant TMZ
(75 mg/m
2/day) for 10 days, and subsequent TMZ
(150 mg/m
2/day every 28 days) for up to 6 cycles in 59
patients with newly diagnosed brain metastases from vari-
ous sources. Median survival was 13 months with 5 com-
plete responses and 21 partial responses being noted to yield
a 44% objective response rate. In another study looking at
brain metastases from a variety of primary sites, Kouvaris
et al., reported the use of combined therapy with WBRT to a
total dose of 36 Gy in 12 fractions given in 16 days along
with TMZ 60 mg/m
2/day (days 1–16) followed by 6 cycles
of TMZ (200 mg/m
2/day for 5 consecutive days every
28 days). Median survival was 12 months with seven
complete responses and 11 partial responses being noted for
an overall objective response rate of 54.5% with the
objective response rate in patients with lung cancer being
78.6%. Interestingly, 45.5% of individuals in this study
experienced hepatotoxicity, attributed to the use of anti-
convulsants in these patients [49]. The improved survival
seen here and in the Addeo et al., study as opposed to the
Margolin study may be more related to the underlying
primary tumor histologies than to the advantage provided
by the alteration in the TMZ administration [37, 49, 52].
One other prospective phase II study of WBRT and
TMZ also included the use of cisplatin but with both
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tot et al., studied 50 patients with NSCLC brain metas-
tases treated with TMZ (200 mg/m
2/day for 5 days every
28 days) and cisplatin (75 mg/m
2) on day 1 of each cycle,
for up to 6 cycles followed by WBRT to a total of 30 Gy
in 10 fractions. WBRT was performed at time of pro-
gressive disease (at any time) or in patients with stable
disease after 4 cycles. Median survival was 5 months and
one complete response and ﬁve partial responses were
noted [56]. Though methodological differences prevent
meaningful comparisons between this and the studies of
Addeo, Kouvaris and Margolin, the addition of cisplatin
did not appear to provide an overt survival or response
beneﬁt.
In the six remaining prospective phase II studies TMZ
was used in combination with a variety of other systemic
agents [41, 42, 46, 47, 50, 51]. These included thalidomide,
cisplatin, vinorelbine, pegylated liposomal doxorubicin,
and lomustine utilized for a variety of tumor types and at
either new diagnosis or at recurrence. Median survival was
as short as 2 months in the report by Larkin et al., who
utilized TMZ at 150 mg/m
2 on days 1 through 5 every
28 days and lomustine 60 mg/m
2 on cycle day 5 every
56 days in patients with newly diagnosed melanoma brain
metastases[51]. The longest median survival in this group
of six studies was 10 months in the report of Caraglia et al.,
who used TMZ at 200 mg/m
2 on days 1 through 5 and
pegylated liposomal doxorubicin at 35 mg/m
2 on day 1 of
every 28 day cycle for up to 8 cycles in individuals with
progressive metastases failing initial therapy. In this study,
only one individual had a melanoma primary[41]. Here
again, the underlying characteristics of the different studies
are too disparate to allow meaningful comparisons to
establish the superiority or inferiority of one regimen to
another. They do, however, reﬂect the known poor prog-
nosis of patients with melanoma once intracranial metas-
tases develop [41, 42, 46, 47, 50, 51].
Prospective phase I studies
There were two prospective phase I studies utilizing TMZ
and other management in the series of papers meeting this
guideline’s criteria [53, 54]. In the ﬁrst Omuro et al.,
describe the use of 28 day cycles of TMZ at 150 mg/m
2 on
days 1 through 7 and 15 through 21 and vinorelbine on
days 1 and 8 using escalating doses with a starting dose of
15 mg/m
2 with increments of 5 mg/m
2 for each cohort of
3–6 patients until 30 mg/m
2. The maximum tolerated dose
was declared at 30 mg/m
2 and, though not a primary goal
of the study, it was noted median survival of the patients
treated was 17 weeks [53]. In the other study Rivera et al.,
looked for a maximum tolerated dose of TMZ and cape-
citabine. Four sequential cohorts were treated at different
dosing levels on days 1 through 5 and days 8 through 12
with cycles repeated every 21 days. Respective dosing
ranges of capecitabine and TMZ were 1600–2000 mg/m
2
and 50–150 mg/m
2. Maximum tolerated dose was not
reached. No median survival was reported but, among the
24 cases enrolled one complete response and two partial
responses were noted [54]. Though these two studies meet
criteria for inclusion in these guidelines, they add little to
development of a consensus on how TMZ, alone or in
combination with other agents would play a role in the
therapy of brain metastases.
Combined subgroup analyses from multiple
publications
Two of the studies involving TMZ therapy of brain
metastases were subgroup analyses combined from prior
prospective studies [39, 40]. Bafaloukos et al., combined
the data from two publications of the Hellenic Coopera-
tive Oncology Group evaluating patients with melanoma
brain metastases. Twenty-ﬁve individuals treated with
TMZ at a dose of 150–200 mg/m
2/day on days 1 through
5 every 4 weeks alone or with either docetaxel (80 mg/m
2
on day 1) or cisplatin (75 mg/m
2 on day 1). Median
survival combining all patients was 4.7 months. Six par-
tial responses were observed distributed between the three
groups. No obvious superiority of one regimen was dis-
cerned over another [39, 57, 58]. In the publication by
Boogerd et al., data was combined from three different
studies. Fifty-two patients with brain metastases were
evaluable who were treated with TMZ at doses from 150
to 250 mg/m
2/day for 5 days every 4 weeks followed by
immunotherapy granulocyte–macrophage-colony stimu-
lating factor (2.5 lg/kg), interleukin-2 (4 MIU/m
2), and
IFNa (5 MIU ﬁxed dose) for 12 days (n = 23) or who
were treated with TMZ alone (200 mg/m
2/day for 5 days
every 4 weeks) (n = 29). Out of the 52 patients the
authors focused on the 13 with evidence of systemic
response noting that their neurologic stabilization or
responses seemed to be more meaningful. The median
survival for all 52 was 5.6 months. The authors were
unable to conclude the superiority of one regimen over
the other [40].
Retrospective case series
The last class III study qualifying for inclusion in this
guideline was a simple retrospective case series of 35
patients, all treated with TMZ (200 mg/m
2 for 5 days every
28 days) with 12 receiving stereotactic radiosurgery and
with ten receiving WBRT. Median survival was 8 months
with one complete response and two partial responses
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authors concluded the results were ‘‘favorable’’ but
appropriately did not attempt to compare the groups for
superiority [45].
Fotemustine
The use of fotemustine was addressed in six studies, one of
which was evidence class I [59] and ﬁve of which were
evidence class III [60–64]. Five of the six included only
brain metastases from melanoma [59–61, 63, 64].
Randomized controlled study
The study by Mornex et al., was a randomized controlled
study of 76 individuals with brain metastases from mela-
noma yielding class I data. Group 1 received fotemustine
intravenously at a dose of 100 mg/m
2 on days 1, 8, and 15
followed by a 5 week rest period followed by a single dose
every 3 weeks thereafter. Group 2 received the same dos-
age regimen of fotemustine with the addition of WBRT at a
dose 37.5 Gy delivered in 15 fractions over 3 consecutive
weeks. Gender, age, extent of systemic disease, and num-
ber of intracranial metastases were balanced. The perfor-
mance status of group 2 was signiﬁcantly better than in
group 1 (p = 0.019). Utilizing intent to treat analysis there
was no difference in survival, response rate (complete
responses combined with partial responses) or tumor con-
trol (deﬁned as complete responses combined with partial
responses and stable disease) between the two groups.
Median time to cerebral progression was longer in the
patients treated with both being 49 days in group 1 and
80 days in group 2 (p = 0.069) [59]. No newer studies of
fotemustine in this patient group have met criteria for
inclusion in this guideline.
Prospective single armed phase II studies
In the class III studies an array of uses of this therapy and
subsequent outcomes can be found. In one study using
fotemustine alone for brain metastases from melanoma
Jacquilat et al., described 39 individuals who had a median
survival of 26 weeks from initiation of therapy. There were
two complete responses and nine partial responses with the
median duration of response being 11 weeks. The prom-
ising nature of this study, published prior to the other
studies meeting criteria for inclusion in this guideline,
likely spurred the additional investigations that have been
noted [63]. Brocker et al., reported the use of WBRT and
fotemustine in 13 patients with melanoma brain metastases
not amenable to surgery or stereotactic radiotherapy, with
seven achieving partial response or stable disease. Among
those seven median survival was 6 months and survival in
the rest was 2 months [60]. In a somewhat larger study
Chang et al., combined fotemustine with dacarbazine in a
group of 34 patients with brain metastases from melanoma
whose median survival was 4.5 months [61]. Cotto et al.,
reported a series of 31 individuals with brain metastases
from NSCLC treated with fotemustine plus cisplatin.
Twenty-ﬁve cases were evaluable for response with two
achieving complete response and two achieving partial
response. Median survival was reported as 16 weeks [62].
Hematologic toxicity in both the Chang and the Cotto
studies was in excess of that seen with the use of fote-
mustine alone as noted by Jacquilat [61–63].
Case series
Ulrich et al., reported their case series of 12 patients with
brain metastases from melanoma who were treated with
induction therapy of fotemustine at 100 mg/m
2 once a
week with simultaneous WBRT to a total dose ranging
from 32 to 58 Gy followed by maintenance treatment with
100 mg/m
2 fotemustine every 4 weeks thereafter. Two of
the 12 individuals received dacarbazine 200 mg/m
2 on
days 3 and 5 of the ﬁrst 2 weeks. Six individuals had
complete or partial intracranial remission and amongst
those the mean survival was 8.2 months [64]. Grade 3 or 4
thrombocytopenia was seen in four cases and grade 3 or 4
leukopenia was seen in four cases. The variation in radia-
tion doses and systemic chemotherapy (16% of cases
receiving dacarbazine) results in the data from this publi-
cation being classiﬁed as class III.
Chemotherapy agent summary
Although class I, II and III data could be discerned from
the literature regarding the use of TMZ and fotemustine in
the treatment of brain metastases, meaningful survival
beneﬁt could only be demonstrated when subjected to
rigorous analysis in patients with melanoma metastases
when added to WBRT. There were numerous reports of
individuals who beneﬁted in one form or another from the
use of these agents and it cannot be concluded that there
might not be a speciﬁc circumstance where TMZ or fote-
mustine are of value in the therapy of brain metastases. To
improve this situation, investigations of these and other
systemically administered agents is clearly warranted.
Molecular targeted agents
Review of the literature provided six unique studies that
met the criteria for support of guidelines recommendations
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management of brain metastases (Table 5).
There is only class III evidence that a molecular targeted
agent, geﬁtinib, results in partial response or stable disease
in approximately 80–90% of patients with brain metastases
due to NSCLC.
Recent advances in the treatment of many malignancies
have frequently been due to the incorporation of molecular
targeted agents into the treatment regimen. In NSCLC the
two categories of molecular targeted agents that have
received the most attention are agents targeting the epi-
dermal growth factor or angiogenesis pathways [65, 66].
The use of RECIST criteria [67] to measure tumor response
to these agents likely underestimates their effectiveness
since prolonged tumor stabilization has been noted with
these agents.
Epidermal growth factor inhibiting agents
Geﬁtinib inhibits numerous tyrosine kinases, including the
epidermal growth factor receptor (EGFR). It can be given
orally and was approved for use in advanced NSCLC.
Erlotinib is another widely used tyrosine kinase inhibitor of
the EGFR receptor. Cetuximab is a monoclonal antibody to
the EGFR receptor and is currently being evaluated in
locally advanced and advanced NSCLC.
Table 5 summarizes the case reports [68–70] and small
single arm prospective studies [71–73] of geﬁtinib for
patients with brain metastases from NSCLC. Most of these
have demonstrated tumor response or stabilization in the
majority of the patients treated. However, it is not generally
used in patients as ﬁrst line treatment for symptomatic brain
metastases and there is no evidence that it should be used
instead of WBRT or other conventional treatments [68–73].
An area of ongoing research is in the predictive value
of EGFR mutations in NSCLC [74]. In eight patients with
brain metastases from lung cancer, Shimato et al.,
reported the association of EGFR mutations with a higher
rate of tumor response/stabilization with geﬁtinib in a
small number of patients. Most of these patients had
previously undergone WBRT and this complicated the
attribution of tumor response or stabilization to geﬁtinib
alone [70].
Angiogenic-inhibiting agents
Agents targeting the angiogenesis pathway include thalid-
omide and bevacizumab. Bevacizumab is a monoclonal
antibody against vascular epidermal growth factor receptor
(VEGFR). Elevated VEGFR has been linked with devel-
opment of brain metastases in murine models of NSCLC
[75]. There are no prospective studies of anti-angiogenesis
agents for brain metastases in humans in part due to concern
regarding the possibility of treatment-related intracranial
bleeding. Prospective studies that have shown a survival
beneﬁt with bevacizumab in patients with non-squamous
NSCLC excluded patients with known brain metastases
[76]. A recently presented study by Akerly et al., concluded
that the use of bevacizumab along with cytotoxic chemo-
therapy agents resulted in only one central nervous system
hemorrhage in a group of 85 patients with non-small cell
carcinoma and known brain metastases [77]. More studies
have been proposed to evaluate the safety of bevacizumab
in patients with brain metastases who undergo WBRT but
no data meeting the criteria for inclusion in a recommen-
dation are available.
Molecular targeted agent summary
The molecular underpinnings of tumor growth are better
understood than ever in the past, but translation of this
information to the treatment of brain metastases has not yet
resulted in robust improvement in treatment outcome
parameters. Isolated cases of treatment response have been
observed with epidermal growth factor inhibiting agents
and angiogenic-inhibiting agents. By no means should
agents related to epidermal growth factor or vascular
endothelial growth factor be viewed as the only candidates
for the targeted therapies of brain metastases. Larger pro-
spective and comparative studies, likely combined with
more standard therapies, will be necessary to determine if
such targeted agents will really contribute to tumor control
and improved survival.
Investigational therapy summary
Not surprisingly, the clinical work done thus far with
newer treatment modalities for metastatic brain tumors
has not provided data that immediately translates into
level 1 recommendations. Some progress has been made
in deﬁning the roll of TMZ in the management of brain
metastases and it is clear that though there is a role it is
limited as noted in the level 2 recommendation provided.
Much of the clinical investigative work completed and
published simply deﬁnes new problems and challenges
with the techniques and agents that can be addressed in
studies with properly asked questions. Thus, investiga-
tions to improve upon weaknesses identiﬁed in the above
discussion continue to be reported. For example, demon-
stration of ongoing research activity for molecular tar-
geted agents such as the assessment of geﬁtinib efﬁcacy,
as well as on a number of other fronts, is evidenced
136 J Neurooncol (2010) 96:115–142
123T
a
b
l
e
5
S
u
m
m
a
r
y
o
f
m
o
l
e
c
u
l
a
r
t
a
r
g
e
t
e
d
a
g
e
n
t
s
F
i
r
s
t
a
u
t
h
o
r
(
y
e
a
r
)
S
t
u
d
y
d
e
s
i
g
n
/
e
v
i
d
e
n
c
e
c
l
a
s
s
I
n
t
e
r
v
e
n
t
i
o
n
s
P
o
p
u
l
a
t
i
o
n
M
e
d
i
a
n
s
u
r
v
i
v
a
l
T
u
m
o
r
r
e
s
p
o
n
s
e
M
e
d
i
a
n
t
i
m
e
t
o
r
e
c
u
r
r
e
n
c
e
/
p
r
o
g
r
e
s
s
i
o
n
G
e
ﬁ
t
i
n
i
b
C
e
r
e
s
o
l
i
[
7
1
]
(
2
0
0
4
)
P
r
o
s
p
e
c
t
i
v
e
s
i
n
g
l
e
a
r
m
s
t
u
d
y
E
v
i
d
e
n
c
e
c
l
a
s
s
I
I
I
G
e
ﬁ
t
i
n
i
b
(
n
=
4
1
)
B
M
f
r
o
m
N
S
C
L
C
5
m
o
n
t
h
s
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
i
n
b
r
a
i
n
:
1
0
%
(
C
R
0
/
4
1
;
P
R
4
/
4
1
)
S
t
a
b
l
e
d
i
s
e
a
s
e
:
7
/
4
1
M
e
d
i
a
n
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
s
u
r
v
i
v
a
l
:
3
m
o
n
t
h
s
C
h
i
u
[
7
2
]
(
2
0
0
4
)
P
r
o
s
p
e
c
t
i
v
e
s
i
n
g
l
e
a
r
m
s
t
u
d
y
E
v
i
d
e
n
c
e
c
l
a
s
s
I
I
I
G
e
ﬁ
t
i
n
i
b
(
n
=
2
1
f
o
r
B
M
s
u
b
-
g
r
o
u
p
)
B
M
f
r
o
m
N
S
C
L
C
N
R
f
o
r
B
M
s
u
b
-
g
r
o
u
p
O
f
8
p
t
s
w
i
t
h
m
e
a
s
u
r
a
b
l
e
B
M
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
i
n
b
r
a
i
n
:
5
0
%
(
C
R
0
/
8
;
P
R
4
/
8
)
(
S
t
a
b
l
e
d
i
s
e
a
s
e
3
/
8
M
e
d
i
a
n
p
r
o
g
r
e
s
s
i
o
n
f
r
e
e
s
u
r
v
i
v
a
l
:
3
.
9
m
o
n
t
h
s
H
o
t
t
a
[
6
8
]
(
2
0
0
4
)
C
a
s
e
s
e
r
i
e
s
E
v
i
d
e
n
c
e
c
l
a
s
s
I
I
I
G
e
ﬁ
t
i
n
i
b
(
n
=
1
4
f
o
r
B
M
s
u
b
-
g
r
o
u
p
)
N
S
C
L
C
;
d
a
t
a
e
x
t
r
a
c
t
e
d
f
o
r
B
M
s
u
b
-
g
r
o
u
p
N
R
f
o
r
B
M
s
u
b
g
r
o
u
p
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
i
n
b
r
a
i
n
:
4
3
%
(
C
R
1
/
1
4
,
P
R
5
/
1
4
)
S
t
a
b
l
e
d
i
s
e
a
s
e
8
/
1
4
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
a
t
e
x
t
r
a
-
c
r
a
n
i
a
l
s
i
t
e
s
:
7
/
1
4
N
R
N
a
m
b
a
[
6
9
]
(
2
0
0
4
)
C
a
s
e
s
e
r
i
e
s
E
v
i
d
e
n
c
e
c
l
a
s
s
I
I
I
G
e
ﬁ
t
i
n
i
b
(
n
=
1
5
)
B
M
f
r
o
m
N
S
C
L
C
8
.
3
m
o
n
t
h
s
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
i
n
b
r
a
i
n
:
6
0
%
(
C
R
1
/
1
5
;
P
R
8
/
1
5
)
S
t
a
b
l
e
d
i
s
e
a
s
e
2
/
1
5
N
R
S
h
i
m
a
t
o
[
7
0
]
(
2
0
0
5
)
C
a
s
e
s
e
r
i
e
s
E
v
i
d
e
n
c
e
c
l
a
s
s
I
I
I
G
e
ﬁ
t
i
n
i
b
(
n
=
8
)
B
M
f
r
o
m
N
S
C
L
C
N
R
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
i
n
b
r
a
i
n
:
5
/
8
p
t
s
O
f
t
h
e
5
p
t
s
w
i
t
h
a
n
o
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
:
3
p
t
s
c
l
a
s
s
i
ﬁ
e
d
a
s
e
f
f
e
c
t
i
v
e
w
i
t
h
g
e
ﬁ
t
i
n
i
b
a
s
r
e
s
p
o
n
s
e
w
a
s
i
n
t
h
e
s
e
t
t
i
n
g
o
f
a
n
u
n
c
o
n
t
r
o
l
l
a
b
l
e
B
M
o
r
n
e
w
B
M
a
f
t
e
r
r
a
d
i
o
t
h
e
r
a
p
y
N
R
W
u
[
7
3
]
(
2
0
0
7
)
P
r
o
s
p
e
c
t
i
v
e
s
i
n
g
l
e
a
r
m
p
h
a
s
e
I
I
s
t
u
d
y
E
v
i
d
e
n
c
e
c
l
a
s
s
I
I
I
G
e
ﬁ
t
i
n
i
b
(
n
=
4
0
)
B
M
f
r
o
m
N
S
C
L
C
s
u
b
-
t
y
p
e
a
d
e
n
o
c
a
r
i
n
o
m
a
1
5
m
o
n
t
h
s
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
i
n
b
r
a
i
n
:
3
8
%
(
C
R
1
/
4
0
;
P
R
1
4
/
4
0
)
S
t
a
b
l
e
d
i
s
e
a
s
e
1
8
/
4
0
P
r
o
g
r
e
s
s
i
v
e
d
i
s
e
a
s
e
7
/
4
0
M
e
d
i
a
n
p
r
o
g
r
e
s
s
i
o
n
f
r
e
e
s
u
r
v
i
v
a
l
:
9
.
0
m
o
n
t
h
s
B
M
B
r
a
i
n
m
e
t
a
s
t
a
s
e
s
,
B
R
B
r
a
i
n
r
e
c
u
r
r
e
n
c
e
(
l
o
c
a
l
?
d
i
s
t
a
n
t
)
,
C
R
C
o
m
p
l
e
t
e
r
e
s
p
o
n
s
e
,
D
R
D
i
s
t
a
n
t
r
e
c
u
r
r
e
n
c
e
i
n
b
r
a
i
n
,
E
R
C
E
v
e
n
t
s
r
e
v
i
e
w
c
o
m
m
i
t
t
e
e
,
F
d
U
r
d
5
-
ﬂ
u
o
r
o
-
2
0
-
d
e
o
x
y
u
r
i
d
i
n
e
,
G
1
G
r
o
u
p
1
,
G
2
G
r
o
u
p
2
,
G
3
G
r
o
u
p
3
,
G
4
G
r
o
u
p
4
,
L
R
L
o
c
a
l
r
e
c
u
r
r
e
n
c
e
a
t
o
r
i
g
i
n
a
l
s
i
t
e
i
n
b
r
a
i
n
,
M
G
d
M
o
t
e
x
a
ﬁ
n
-
g
a
d
o
l
i
n
i
u
m
,
N
R
N
o
t
r
e
p
o
r
t
e
d
,
N
S
N
o
t
s
i
g
n
i
ﬁ
c
a
n
t
,
N
S
C
L
C
N
o
n
-
s
m
a
l
l
c
e
l
l
l
u
n
g
c
a
n
c
e
r
,
O
R
O
b
j
e
c
t
i
v
e
r
e
s
p
o
n
s
e
,
P
R
P
a
r
t
i
a
l
r
e
s
p
o
n
s
e
,
P
t
s
P
a
t
i
e
n
t
s
,
R
C
T
R
a
n
d
o
m
i
z
e
d
c
o
n
t
r
o
l
t
r
i
a
l
,
S
R
S
S
t
e
r
e
o
t
a
c
t
i
c
r
a
d
i
o
s
u
r
g
e
r
y
,
T
M
Z
T
e
m
o
z
o
l
o
m
i
d
e
,
W
B
R
T
W
h
o
l
e
-
b
r
a
i
n
r
a
d
i
a
t
i
o
n
t
h
e
r
a
p
y
J Neurooncol (2010) 96:115–142 137
123through reports at national meetings [78]. Even when no
speciﬁc positive level 1 recommendations can be made, it
is still appropriate to encourage enrollment in properly
designed and conducted clinical trials of new treatment
modalities and agents.
Key issues for future investigation
New modalities in the therapy of metastatic brain tumors
need not be limited to the radiation therapy, radiation
sensitizers, chemotherapy and molecular targeted agents
mentioned in this guideline. Assessment of alternative
types of radiation, improved radiation planning systems,
improved radiation and chemotherapy targeting systems
and assessment of other tumor metabolic pathways for
targeting are critical to making progress against this broad
ranging disease. Enrollment of patients in properly con-
ducted studies of each of these agents and modalities is
warranted in order to learn their true value.
Use of nanoparticle technology for identifying tumors,
targeting therapy and assessing response early in therapy
warrants particular attention. Investigation of other methods
of molecular imaging, for instance with MRI or positron
emission tomography, may result in better methods of early
detection of therapeutic efﬁcacy or failure helping to mini-
mize time wasted on ineffective treatments. Improved
radiationandsystemictreatmentplanningandtargetingmay
decreasetoxicitytonormalcerebraltissueimprovingquality
of life even though disease control may not be impacted.
An exhaustive list of biologic issues that should be
addressed in the therapy of cerebral metastases cannot be
provided here but the following highlights should serve as
inspiration to motivated investigators. Though EGFR and
VEGFR are recognized as being important in many tumor
types, they are but one avenue by which disordered
molecular signaling provides proliferative advantage.
Metastatic tumor cell resistance to standard alkylating
agents is yet to be addressed effectively, especially in the
central nervous system. The importance of tumor stem cells
in metastatic brain lesions has yet to be deﬁned in detail.
Though the blood brain barrier is not generally an issue in
larger brain metastases, the possibility of smaller clusters
of cells with growth potential being shielded from therapy
by this structure must be investigated.
The following is a list of major ongoing or recently
closed randomized clinical trials pertaining to the use of
emerging therapies that evaluate treatment comparisons
addressed by this guideline paper for the management of
brain metastases.
1. Temozolomide for Treatment of Brain Metastases
From Non-Small Cell Lung Cancer (Study
P03247AM3) (COMPLETED)
Ofﬁcial title: A Randomized, Open-Label Phase 2
Study of Temozolomide Added to Whole Brain
Radiation Therapy Versus Whole Brain Radiation
Therapy Alone for the Treatment of Brain Metastasis
From Non-Small Cell Lung Cancer
Status: Completed
Clinicaltrials.gov Identiﬁer: NCT00076856
Principal Investigator: Not provided
Location: Not provided
Sponsors and Collaborators: Schering-Plough
2. Study of Temozolomide in the Treatment of Brain
Metastasis From Non-Small-Cell Lung Cancer (Study
P02143) (COMPLETED)
Ofﬁcial title: A Phase II Study of Temozolomide
(SCH 52365) in Subjects with Brain Metastasis from
Non-Small-Cell Lung Cancer
Status: Completed
Clinicaltrials.gov Identiﬁer: NCT00034697
Principal Investigator: Not provided
Location: Not provided
Sponsors and Collaborators: Schering-Plough
3. Safety and Tolerability of Low-Dose Temozolomide
During Whole Brain Radiation in Patients With
Cerebral Metastases From Non-Small-Cell Lung Can-
cer (Study P04071) (TERMINATED)
Ofﬁcial title: Randomized Phase II Study: Temozol-
omide (TMZ) Concomitant to Radiotherapy Followed
by Sequential TMZ in Advanced NSCLC Patients
With CNS Metastasis Versus Radiotherapy Alone
Status: Terminated (Phase II)
Clinicaltrials.gov Identiﬁer: NCT00266812
Principal Investigator: Not provided
Location: Not provided
Sponsors and Collaborators: Schering-Plough, AES-
CA Pharma GmbH
4. Radiation Therapy With or Without Temozolomide in
Treating Patients With Non-Small Cell Lung Cancer
That is Metastatic to the Brain
Ofﬁcial title: A Phase II Study Of Temozolomide
(SCH 52365) In Subjects With Brain Metastasis From
Nonsmall Cell Lung Cancer
Status: Active, not recruiting (Phase II)
Clinicaltrials.gov Identiﬁer: NCT00030836
Principal Investigator: Lauren E. Abrey, MD,
Memorial Sloan-Kettering Cancer Center
Location: United States
Sponsors and Collaborators: Memorial Sloan-Ket-
tering Cancer Center, National Cancer Institute (NCI)
5. Temozolomide With or Without Radiation Therapy to
the Brain in Treating Patients With Stage IV Mela-
noma That Is Metastatic to the Brain
Ofﬁcial title: Temozolomide Versus Temozolo-
mide ? Whole Brain Radiation In Stage IV Melanoma
138 J Neurooncol (2010) 96:115–142
123Patients With Asymptomatic Brain Metastases
Status: Active, not recruiting (Phase III)
Clinicaltrials.gov Identiﬁer: NCT00020839
Principal Investigator: Juergen C. Becker, MD, PhD
Universitaets-Hautklinik Wuerzburg
Location: Europe (33 locations)
Sponsors and Collaborators: European Organization
for Research and Treatment of Cancer
6. Radiation Therapy Combined With Either Geﬁtinib or
Temozolomide in Treating Patients With Non-Small
Cell Lung Cancer and Brain Metastases
Ofﬁcial title: Whole Brain Radiotherapy in Combi-
nation With Geﬁtinib (Iressa) or Temozolomide
(Temodal) for Brain Metastases From Non-Small
Lung Cancer (NSCLC) A Randomized Phase II Trial
Status: Recruiting (Phase II)
Clinicaltrials.gov Identiﬁer: NCT00238251
Principal Investigators: Study Chair: Gianfranco
Pesce, MD Oncology Institute of Southern Switzerland
Investigator: Roger Stupp, MD Centre Hospitalier
Universitaire Vaudois
Location: Switzerland
Sponsors and Collaborators: Swiss Group for Clin-
ical Cancer Research
7. Radiation Therapy and Stereotactic Radiosurgery With
or Without Temozolomide or Erlotinib in Treating
Patients With Brain Metastases Secondary to Non-
Small Cell Lung Cancer
Ofﬁcial title: A Phase III Trial Comparing Whole
Brain Radiation And Stereotactic Radiosurgery Alone
Versus With Temozolomide Or Erlotinib In Patients
With Non-Small Cell Lung Cancer And 1–3 Brain
Metastases
Status: Recruiting (Phase III)
Clinicaltrials.gov Identiﬁer: NCT00096265
Principal Investigators:
Paul Sperduto, MD, MAPP Park Nicollet Cancer
Center
Minesh P. Mehta, MD University of Wisconsin,
Madison
H. I. Robins, MD, PhD University of Wisconsin,
Madison
Location: United States and Canada (56 locations)
Sponsors and Collaborators: Radiation Therapy
Oncology Group, National Cancer Institute (NCI)
8. Comparison Study of WBRT and SRS Alone Versus
With Temozolomide or Erlotinib in Patients With
Brain Metastases of NSCLC
Ofﬁcial title: A Phase III Trial Comparing Whole
Brain Radiation (WBRT) and Stereotactic Radiosur-
gery (SRS) Alone Versus With Temozolomide or
Erlotinib in Patients With Non-Small Cell Lung
Cancer and 1–3 Brain Metastases
Status: Recruiting (Phase III)
Clinicaltrials.gov Identiﬁer: NCT00268684
Principal Investigator: Felix Bokstein, M.D. Tel-
Aviv Sourasky Medical Center
Location: Israel
Sponsors and Collaborators: Tel-Aviv Sourasky
Medical Center, RTOG
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